Advertisement

Topics

LDL-C Plunges on Novel Anti-PCSK9 Agent Inclisiran: ORION-1

04:30 EDT 18 Mar 2017 | Medscape

LDL-C levels fell by more than one-half over 6 months at the highest studied dosage of the drug, which "silences" RNA involved in PCSK9 synthesis, in this randomized phase 2 trial.
Heartwire from Medscape

Original Article: LDL-C Plunges on Novel Anti-PCSK9 Agent Inclisiran: ORION-1

NEXT ARTICLE

More From BioPortfolio on "LDL-C Plunges on Novel Anti-PCSK9 Agent Inclisiran: ORION-1"

Quick Search
Advertisement
 

Relevant Topic

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...